【摘要】 目的探讨替加环素联合头孢哌酮/舒巴坦治疗泛耐药鲍氏不动杆菌的临床疗效,为合理选用抗菌药物提供临床依据。方法回顾性分析2012年3-10月3例使用替加环素联合头孢哌酮/舒巴坦治疗泛耐药鲍氏不动杆菌感染重症患者临床资料,对其临床疗效进行评价。结果 3例患者均多次检出泛耐药鲍氏不动杆菌,体外药敏试验提示对替加环素敏感,对头孢哌酮/舒巴坦中介或耐药,选用替加环素联合头孢哌酮/舒巴坦抗感染治疗,1例治愈,2例改善,其中有1例细菌得到清除,疗程8～16d,临床疗效较满意。结论替加环素联合头孢哌酮/舒巴坦对泛耐药鲍氏不动杆菌清除效果尚不明确,但能取得满意的临床疗效。更多还原

【Abstract】 OBJECTIVE To explore the clinical therapeutic effect of the tigecycline combined with cefoperazone-sulbactam on treatment of pandrug-resistant Acinetobacter baumannii infection so as to guide the reasonable clinical medication.METHODS A total of 3 cases of patients,who used the tigecycline combined with cefoperazone-sulbactam for the treatment of severe pandrug-resistant A.baumannii infections from Mar 2012 to Oct 2012,were retrospectively analyzed,and the therapeutic effects were observed.RESULTS The pandrug-resistant A.baumannii strains were frequently detected in the three patients,and the in vitro drug susceptibility testing indicated that the strains were sensitive to tigecycline,and were intermediate or resistant to cefoperazone-sulbactam.Of the patients treated with the tigecycline combined with cefoperazone-sulbactam,there were 1 case cured and 2 cases improved,one of which was with the bacteria eliminated.The treatment course varied from 8 days to 16 days,and the clinical therapeutic effect was satisfying.CONCLUSION The effect of the tigecycline combined with cefoperazone-sulbactam on the clearance of the pandrug-resistant A.baumannii remains unclear,but the clinical therapeutic effect is satisfying.更多还原